Incidence, clinical, risk factors and outcomes of Guillain-Barre in Covid-19
Fragiel, Marcos; Miro, Oscar; Llorens, Pere; Jimenez, Sonia; Pinera, Pascual; Burillo, Guillermo; Martin, Alfonso; Martin-Sanchez, Francisco J.; Garcia-Lamberechts, Eric J.; Jacob, Javier; Alquezar-Arbe, Aitor; Juarez, Ricardo; Jimenez, Blas; Del Rio, Rigoberto; Mateo Roca, Miriam; Garcia, Arturo H.; Lopez Laguna, Nieves; Lopez Diez, Maria P.; Pedraza Garcia, Jorge; de Simon Almela, Amparo Fernandez; Lopez Diaz, Juan J.; Eiroa Hernandez, Patricia; Ruiz de Lobera, Noemi; Porta-Etessam, Jesus; Fernandez Perez, Cristina; CaIvo, Elpidio; Gonzalez Del Castillo, Juan
Publicación: ANNALS OF NEUROLOGY
2020
VL / 89 - BP / 598 - EP / 603
abstract
We diagnosed 11 Guillain-Barre syndrome (GBS) cases among 71,904 COVID patients attended at 61 Spanish emergency departments (EDs) during the 2-month pandemic peak. The relative frequency of GBS among ED patients was higher in COVID (0.15 parts per thousand) than non-COVID (0.02 parts per thousand) patients (odds ratio [OR] = 6.30, 95% confidence interval [CI] = 3.18-12.5), as was the standardized incidence (9.44 and 0.69 cases/100,000 inhabitant-years, respectively, OR = 13.5, 95% CI = 9.87-18.4). Regarding clinical characteristics, olfactory-gustatory disorders were more frequent in COVID-GBS than non-COVID-GBS (OR = 27.59, 95% CI = 1.296-587) and COVID-non-GBS (OR = 7.875, 95% CI = 1.587-39.09) patients. Although COVID-GBS patients were more frequently admitted to intensive care, mortality was not increased versus control groups. Our results suggest SARS-CoV-2 could be another viral infection causing GBS. ANN NEUROL 2020
MENTIONS DATA
Publicaciones similares en Neuroscience & Behavior
